| 1. |
|
|
| 2. |
- Adam, A, et al.
(författare)
-
Abstracts from Hydrocephalus 2016.
- 2017
-
Ingår i: Fluids and Barriers of the CNS. - : Springer Science and Business Media LLC. - 2045-8118. ; 14:Suppl 1
-
Tidskriftsartikel (refereegranskat)
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
- Joensuu, Heikki, et al.
(författare)
-
Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer The SOLD Randomized Clinical Trial
- 2018
-
Ingår i: JAMA Oncology. - : AMER MEDICAL ASSOC. - 2374-2437 .- 2374-2445. ; 4:9, s. 1199-1206
-
Tidskriftsartikel (refereegranskat)abstract
- Importance: Trastuzumab plus chemotherapy is the standard adjuvant treatment for patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. While the standard duration of trastuzumab treatment is 12 months, the benefits and harms of trastuzumab continued beyond the chemotherapy are unclear.Objective: To evaluate the efficacy and safety of adjuvant trastuzumab continued beyond chemotherapy in women treated with up-front chemotherapy containing a taxane and trastuzumab.Design, Setting, and Participants: Open-label, randomized (1:1) clinical trial including women with HER2-positive breast cancer. Chemotherapy was identical in the 2 groups, consisting of 3 cycles of 3-weekly docetaxel (either 80 or 100 mg/m2) plus trastuzumab for 9 weeks, followed by 3 cycles of fluorouracil, epirubicin, and cyclophosphamide. Thereafter, no trastuzumab was administered in the 9-week group, whereas controls received trastuzumab to complete 1 year of administration. Disease-free survival (DFS) was compared between the groups using a Cox model and the noninferiority approach. The estimated sample size was 2168 patients (1-sided testing, with a relative noninferiority margin of 1.3). From January 3, 2008, to December 16, 2014, 2176 patients were accrued from 7 countries.Intervention: Docetaxel plus trastuzumab for 9 weeks, followed by 3 cycles of fluorouracil, epirubicin, and cyclophosphamide in both groups. Controls continued trastuzumab to 1 year.Main Outcomes and Measures: The primary objective was DFS; secondary objectives included distant disease–free survival, overall survival, cardiac DFS, and safety.Results: In the 2174 women analyzed, median age was 56 (interquartile range [IQR], 48-64) years. The median follow-up was 5.2 (IQR, 3.8-6.7) years. Noninferiority of the 9-week treatment could not be demonstrated for DFS (hazard ratio, 1.39; 2-sided 90% CI, 1.12-1.72). Distant disease–free survival and overall survival did not differ substantially between the groups. Thirty-six (3%) and 21 (2%) patients in the 1-year and the 9-week groups, respectively, had cardiac failure; the left ventricle ejection fraction was better maintained in the 9-week group. An interaction was detected between the docetaxel dose and DFS; patients in the 9-week group treated with 80 mg/m2 had inferior and those treated with 100 mg/m2 had similar DFS as patients in the 1-year group.Conclusions and Relevance: Nine weeks of trastuzumab was not noninferior to 1 year of trastuzumab when given with similar chemotherapy. Cardiac safety was better in the 9-week group. The docetaxel dosing with trastuzumab requires further study.Trial Registration: ClinicalTrials.gov Identifier: NCT00593697
|
|
| 9. |
|
|
| 10. |
|
|
| 11. |
- Penttilä, S., et al.
(författare)
-
Late-onset spinal motor neuronopathy - A common form of dominant SMA
- 2014
-
Ingår i: Neuromuscular Disorders. - : Elsevier BV. - 0960-8966. ; 24:3, s. 259-268
-
Tidskriftsartikel (refereegranskat)abstract
- We previously described two Finnish families with a new autosomal dominant late-onset spinal motor neuronopathy that was mapped to chromosome 22q11.2-q13.2. In the current screening study of 43 lower motor neuron disease patients from Finland and Sweden, we identified 26 new late-onset spinal motor neuronopathy patients sharing the founder haplotype. In addition to the main symptoms and signs: painful cramps, fasciculations, areflexia and slowly evolving muscle weakness, new features such as mild bulbar findings, were identified. The disease is relatively benign in terms of life expectancy and rate of disability progression, and it is therefore noteworthy that three patients were initially misdiagnosed with ALS. Significant recombinants in this new patient cohort restricted the disease locus by 90% to 1.8. Mb. Late-onset spinal motor neuronopathy seems not to be very rare, at least not in Finland, with 38 patients identified in a preliminary ascertainment. © 2013 Elsevier B.V.
|
|
| 12. |
|
|
| 13. |
|
|
| 14. |
- Warnecke, H., et al.
(författare)
-
New metrological capabilities for measurements of dynamic liquid flows
- 2022
-
Ingår i: Metrologia. - : IOP Publishing Ltd. - 0026-1394 .- 1681-7575. ; 59:2
-
Tidskriftsartikel (refereegranskat)abstract
- The capability to calibrate flow and volume devices dynamically has gained increasing interest over the years. Within the scope of the EMPIR project 17IND13 'Metrology for real-world domestic water metering', several test rigs were developed with which dynamic flow profiles can be generated and measured that reflect characteristics of real-world drinking water consumption. The dynamic component of the test rigs is realized based on different technologies such as valves, cavitation nozzles or piston provers. For validation purposes, an intercomparison of the test rigs was carried out in the scope of an EURAMET pilot study no. 1506. Between September 2020 and February 2021, a transfer standard specially developed for the intercomparison was calibrated at eight laboratories. The measurement error was determined for three dynamic flow profiles representative of drinking water consumption in Europe. In addition to determining the measurement errors and the degree of equivalence, five additional key parameters were derived to characterize the test rig properties: (1) repeatability of the profile measurements, (2) mean value of the residuals, (3) deviation between measured total mass and total mass resulting from the given profile and (4) duration of the flow change for an increasing change (5) and duration of the flow change for a decreasing change. These key parameters comprehensively describe the quality with which the dynamic flow profiles were generated and measured on the test rigs and can be used for evaluations in future intercomparisons of this kind. A main outcome of the intercomparison is that there is no technology to be preferred in terms of technical implementation. All test rigs agree well with each other, taking into account their expanded measurement uncertainties.
|
|
